Edinburgh Research Explorer

Tackling gaps in developing life-changing treatments for dementia

Research output: Contribution to journalArticle

  • Caroline L Benn
  • John Davis
  • Gerry Dawson
  • Lee Dawson
  • Alison Evans
  • Nick Fox
  • John Gallacher
  • Mike Hutton
  • John Isaac
  • Declan N C Jones
  • Lesley Jones
  • Giovanna Lalli
  • Vincenzo Libri
  • Simon Lovestone
  • Rui Mauricio
  • Catherine Moody
  • Wendy Noble
  • Hugh Perry
  • James Pickett
  • David Reynolds
  • John Rohrer
  • Carol Routledge
  • James Rowe
  • Heather Snyder
  • Jina Swartz
  • Luc Truyen
  • Paul Whiting

Related Edinburgh Organisations

Open Access permissions

Open

Documents

Original languageEnglish
Pages (from-to)241-253
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Volume5
Early online date24 Jun 2019
DOIs
Publication statusE-pub ahead of print - 24 Jun 2019

Abstract

Since the G8 dementia summit in 2013, a number of initiatives have been established with the aim of facilitating the discovery of a disease-modifying treatment for dementia by 2025. This report is a summary of the findings and recommendations of a meeting titled “Tackling gaps in developing life-changing treatments for dementia”, hosted by Alzheimer's Research UK in May 2018. The aim of the meeting was to identify, review, and highlight the areas in dementia research that are not currently being addressed by existing initiatives. It reflects the views of leading experts in the field of neurodegeneration research challenged with developing a strategic action plan to address these gaps and make recommendations on how to achieve the G8 dementia summit goals. The plan calls for significant advances in (1) translating newly identified genetic risk factors into a better understanding of the impacted biological processes; (2) enhanced understanding of selective neuronal resilience to inform novel drug targets; (3) facilitating robust and reproducible drug-target validation; (4) appropriate and evidence-based selection of appropriate subjects for proof-of-concept clinical trials; (5) improving approaches to assess drug-target engagement in humans; and (6) innovative approaches in conducting clinical trials if we are able to detect disease 10–15 years earlier than we currently do today.

ID: 91831334